Introduction
Tumor progression is dependent on a number of cellular events, including cell proliferation, migration, resistance to host immune defense, and angiogenesis.
Transforming growth factor-β1 (TGF-β1) is a multifunctional cytokine involved in the regulation of almost every aspect of cellular behavior, such as cell proliferation, differentiation, and migration [1, 2] . TGF-β1 has also been widely implicated in the regulation of cancer; initially as a tumor suppressor and at later stages as a promoter of tumor progression [3] [4] [5] . Excess TGF-β1 produced by tumor cells is suggested to act on the host to suppress immune surveillance, increase angiogenesis, and promote tumor cell survival and metastasis [6] [7] [8] [9] . In breast cancer patients, an increased expression of TGF-β1 has been shown to correlate with metastatic disease and poor prognostic outcome [10] [11] [12] . Moreover, TGF-β1 activity may prime primary breast tumors for lung metastasis seeding [13] .
Proteolytic remodeling of the extracellular environment is pivotal for the invasion and migration of cancer cells into the stroma. Matrix metalloproteinases (MMPs) play an important role in this remodeling and in the regulation of bioavailability of several growth factors, cytokines, and adhesion factors [14] [15] [16] . Depending on tissue distribution and expression levels of individual MMPs and endogenous inhibitors of their activity, these enzymes may either promote or inhibit tumor progression. Lately is has been shown that up-regulation of endogenous MMPs decrease angiogenesis in tumors by the release of matrix-associated anti-angiogenic factors such as angiostatin, tumstatin, and endostatin [17] [18] [19] [20] [21] . MMPs have been associated with a positive regulation of TGF-β activity and cell responsiveness to TGF-β [22] . However, it has been demonstrated that only cell surface-localized and not soluble extracellular MMP-2 and MMP-9 activity have the ability to promote tumor invasion and angiogenesis and to activate TGF-βs [23] . To our knowledge, it is unknown if also soluble extracellular MMP activity affects TGF-β1 levels.
Sex steroids play an important role in breast carcinogenesis and progression and the majority of breast cancers are hormone dependent. Anti-estrogens, such as the synthetic, non-steroidal compound tamoxifen, and aromatase inhibitors, are cornerstones in the medical treatment of breast cancer. We have previously reported that tamoxifen treatment of experimental breast cancer, both in vitro and in vivo, induces an anti-angiogenic response [20, [24] [25] [26] . We recently showed that tamoxifen significantly up-regulated the expression and activity of MMP-9, whereas estradiol treatment decreased MMP-9 activity levels [20] . Moreover, over-expression of MMP-9 in solid MCF-7 tumors in vivo induced tumor regression and the release of extracellular endostatin [27] .
In this paper, we investigated if the increased levels and activity of extracellular, soluble MMP-9 induced by tamoxifen, affected TGF-β1 levels. We show that long-term tamoxifen treatment decreased the secreted levels of TGF-β1 whereas estradiol increased these levels. In vivo, in solid breast cancer explants in mice, tamoxifen treatment significantly decreased TGF-β1 protein levels and decreased angiogenesis.
Moreover, in vitro experiments showed that inhibition of MMP-9 restored the TGF-β1 levels, suggesting that MMP-9 activity is involved in the negative regulation of tumor TGF-β1 by tamoxifen.
Materials and methods

Cell culture
MCF-7 (HTB-22; human breast adenocarcinoma, ER+ and PR+) cells were obtained from ATCC (Manassas, VA, USA). Cells were cultured in DMEM without phenol red supplemented with 2 mM glutamine, 50 IU/ml penicillin-G, 50 µg/ml streptomycin, and 10% fetal bovine serum, at 37°C in a humidified atmosphere of 5 % CO 2 . Cell culture medium and additives were obtained from Invitrogen (Carlsbad, CA, USA) if not otherwise stated.
Hormone treatment of MCF-7 cells in culture
Confluent cells were trypsinized (0.05% trypsin and 0.02% EDTA) and seeded into without phenol red, supplemented with 10 µg/ml transferrin (Sigma), 1 µg/ml insulin (Sigma), and 0.2 mg/ml BSA (Sigma). The hormone medium was changed every 24
hours. Control cells were incubated with hormone medium supplemented with vehicle, ethanol, and equivalent to the hormone treated groups (0.001%). After hormone treatment, cells and conditioned medium were harvested.
Total protein content was determined using Bio-Rad Protein Assay with bovine serum albumin as standard (Bio-Rad Laboratories, Stockholm, Sweden). Samples were stored at -70°C until subsequent analyses.
MCF-7 tumor explants in mice
Female athymic nude mice (6-8-weeks-old) were purchased from Taconic Frozen tumor tissue was placed in 500 µl ice-cold PBS and immediately homogenized for 30 s on ice at 24000 rpm by using a Polytron PT3000 (Kinematica AG, Littau, Switzerland). The tumor tissue homogenates was centrifuged at 11000 rpm for 5 minutes in an Eppendorf 5417R microcentrifuge (Eppendorf, Hamburg, Germany), and the supernatant was collected and stored in aliquots at -70°C Bio-Rad Protein Assay with bovine serum albumin as standard (Bio-Rad Laboratories, Stockholm, Sweden).
Quantification of TGF-β1 and MMP-9
Supernatant from tumor tissue homogenates, as well as cell lysate and conditioned medium from hormone-treated MCF-7 cells, were analyzed for TGF-β1 and MMP-9
proteins using commercial quantitative immunoassay kits (human TGF-β1 Quantikine 
Quantification of MMP-9 activity in vitro
The activity of MMP-9 was assayed using a gelatinase activity assay. 
Inhibition of MMP-9
MCF-7 cells were treated with 1x10 -6 M tamoxifen for 7 days in hormone medium. 
Immunohistochemistry of TGF-β1 and MMP-9
Formalin-fixed, paraffin embedded tumor tissue biopsies were cut in 5 μm sections, deparaffinized and subjected to anti-TGF-β1 and anti-MMP-9 immunohistochemistry (mouse anti-TGF-β1, dilution 1:20, R&D Systems and rabbit anti-human MMP-9, dilution 1:50, Chemicon Int. Inc. CA, USA with HRP-DAB detection, R&D Systems).
Sections were counterstained with Mayer's hematoxylin and coverslipped in Mountex.
Negative controls (primary antibody omitted) did not show staining. For quantification of the staining all sections were first scanned to identify the range of intensity of the staining. In a blinded manner ten high power fields (x200) per section were examined and scored either as weakly or strongly positive.
Quantification of tumor microvessel area
Formalin-fixed, paraffin-embedded tumors were cut in 3-µm sections, deparaffinized, and subjected to anti-von Willebrand's factor (rabbit anti-human von Willebrand; dilution 1:1000; with Envision detection, DakoCytomation). Sections were counterstained with Mayer's hematoxylin. Negative controls did not show staining. In a blinded manner, 10 high power fields (x200) were examined by section of three different tumors in each group. Vessel quantification of tumor sections was conducted as described previously using a Nikon microscope equipped with a digital camera [28] .
Percentage of area stained positively for von Willebrand's factor was assessed using Easy Image Measurement software (Bergstrom Instruments). Tumor sections were also subjected to H&E staining.
Statistical analysis. Statistical analysis was performed using SPSS software. Oneway ANOVA, Fisher's exact test, and Student's t-test were used where appropriate. All statistical tests were two-sided. Results are expressed as mean ± SEM. Statistical significance was assumed at P values less than 0.05.
Results
Long-term treatment with tamoxifen decreased TGF-β1 protein expression in conditioned media from cultured human breast cancer cells, but did not alter the intracellular levels
To examine the effects of estradiol and/or tamoxifen TGF-β1 expression in breast tumor cells, hormone-responsive MCF-7 cells in culture were treated with estradiol and/or tamoxifen, or a combination of estradiol and tamoxifen, for 24 and 72 hours and 7 days respectively. The levels of TGF-β1 protein secreted from the MCF-7 cells were quantified. As previously shown by others, we found that 24 hours of tamoxifen treatment gave a significant increase in TGF-β1 protein levels in conditioned media [P<0.001, as compared to control] (Fig. 1A) , whereas estradiol or a combination of estradiol and tamoxifen had no significant effect. At 72 hours there were no differences between the groups (Fig. 1B) . However, short term exposure does not represent clinical treatment with tamoxifen; therefore, we chose to expose MCF-7 cells to tamoxifen for a longer period of time, 7 days. Due to the growth inhibitory/ cytotoxic effects of tamoxifen, one week is the maximum time length for which it is possible to treat the tumor cells in vitro. Contrary to the short-term treatment, we found that treating MCF-7 cells with tamoxifen for 7 days significantly decreased TGF-β1 protein levels in conditioned media, compared to control [P<0.001] (Fig. 1C) . Exposure to estradiol for 7 days induced a significant increase of TGF-β1 [P<0.001] (Fig. 1C) . Also, adding tamoxifen to the estradiol treatment triggered a significant decrease in TGF-β1 levels compared to treating cells with estradiol only [P<0.001] (Fig. 1C) . At 7 days TGF-β1
was also analyzed without acid activation of the samples to distinguish between endogenous active and latent forms. Using this approach, very low levels of TGF-β1 Further, to investigate if tamoxifen also affected the intracellular levels of TGF-β1 protein after 7 days of exposure, we analyzed whole-cell lysates. As shown in Fig. 1D, we observed that the intracellular levels were not significantly altered following 7 days of treatment with neither tamoxifen nor estradiol, as compared to control.
Inhibiting extracellular MMP activity restored the tamoxifen-induced decrease in TGF-β1
We have previously reported that prolonged tamoxifen treatment up-regulates MMP-9 expression in cultured MCF-7 cells in vitro and in solid MCF-7 tumors in nude mice [20, 26] . To further investigate if these previous findings of increased MMP-9 levels by tamoxifen were involved in TGF-β1 regulation, experiments with this treatment were set-up. We confirm in the present paper that tamoxifen increased the extracellular protein levels of MMP-9 after 7 days [P<0.001, compared to control] (Fig. 2C ). In addition, Fig. 2A shows that tamoxifen altered the levels also after 24 hours, however the changes were not as profound as after one week [P<0.05, compared to control] ( Fig.   2A ).
MMPs are tightly regulated at the post-transcriptional and/or the post-translational level, and it is therefore imperative to investigate these proteases in the extracellular space where they are biologically active. In this regard, we have previously shown tamoxifen may also alter the extracellular levels of natural inhibitors of MMPs [26] . Therefore, we verified if the altered MMP-9 protein levels also affected the extracellular physiological MMP activity using a substrate activity assay. Our results show that although tamoxifen affects the protein levels of MMP-9 after short-term treatment of 24 hours, this did not lead to an increase in extracellular activity of MMP-9 (Fig. 2B) 2D ). It should be stated that the fluorogenic substrate used in the activity assay may also be cleaved by MMP-2; however, as we have showed previously, the induced levels of active MMP-2 in MCF-7 cells are considerably lower than the levels of active MMP-9 [26] .
Given the significant effect on the extracellular activity of MMP-9 and extracellular TGF-β1 levels after one week of tamoxifen treatment, we thereafter tested the hypothesis of MMP-9 activity being involved in the down-regulation of TGF-β1 by tamoxifen. MCF-7 cells were treated with tamoxifen in combination a synthetic inhibitor of MMP-9 (control cells were incubated with vehicle only) and thereafter measured TGF-β1 in conditioned media. Indeed, as Fig. 3 shows, we detected a significant increase in TGF-β1 protein levels in conditioned media following MMP-9 inhibition [P<0.01, as compared to control] (Fig. 3) . To mimic the treatment situation in our in vivo model, cells were also treated with estradiol+tamoxifen together with the MMP-inhibitor. Inhibiting MMP-activity in this treatment combination also restored the TGF-β1 levels in a similar fashion as in the tamoxifen exposed group; from 918±78 pg/mg protein in the control group versus 1511±151 pg/mg protein in the hormone exposed group, P<0.01. To rule out un-specific effects such as inhibition of other MMPs or ADAMs by the synthetic inhibitor we confirmed our results using a neutralizing specific MMP-9 antibody, which inhibits the enzymatic activity of MMP-9.
In a similar manner as the synthetic inhibitor the specific anti-MMP-9 at two different concentrations also restored the TGF-β1 levels significantly compared to control cells exposed to isotype IgG, Fig. 3 .
Tamoxifen treatment decreased the levels of TGF-β1 and increased the levels of MMP-9 in solid MCF-7 tumors growing in nude mice
To further explore the effects of tamoxifen on TGF-β1, we extended our investigations to an in vivo model of solid MCF-7 tumors growing in nude mice. These tumors require estrogen for growth in nude mice; therefore, a non-treated control group is not possible to achieve in vivo. Moreover, maintaining the mice with a physiologic level of estradiol during tamoxifen treatment mimics a clinical situation in premenopausal women.
Following 2 weeks of treatment, tumors in the estradiol+tamoxifen group were significantly smaller than those in the estradiol group, where tumor volume kept increasing. After 2 weeks the animals were sacrificed and the tumors excised. Tumor tissue homogenates were analyzed for TGF-β1 protein using quantitative ELISA. As Mice were treated as described in Figure 4 . Tumor sections were stained with anti-von Willenbrand's factor and vessel area was counted on tumor sections. Representative sections from estradiol (E2) and estradiol+tamoxifen (E2+Tam) exposed tumors. Tumor vessel area quantification was conducted as described in the materials and methods section. Error bars represent S.E.M.
Discussion
In this study we show that the anti-estrogen tamoxifen, alone or in combination with estradiol, negatively regulate extracellular TGF-β1 protein levels and extracellular MMP-9 activity in ER+ and PR+ human breast cancer cells (MCF-7). The intracellular protein levels of TGF-β1 were unaffected by tamoxifen treatment, indicating a posttranslational regulation of TGF-β1. By inhibiting the activity of MMP-9 the extracellular TGF-β1 levels were restored, suggesting that the down-regulation of TGF-β1 by tamoxifen is mediated, at least in part, by extracellular MMP activities. Our in vitro findings were verified in vivo in nude mice bearing MCF-7 tumor cell explants, where tamoxifen treatment in combination with a physiological level of estradiol decreased TGF-β1 levels compared with estradiol treatment only. Moreover, this was associated with reduced tumor growth as well as significantly decreased angiogenesis.
In addition to the inhibitory effects on proliferation/apoptosis, tamoxifen may also contribute to suppressing tumor growth by decreasing angiogenesis in breast cancer. We have shown in previous studies that tamoxifen decrease pro-angiogenic factors like VEGF and increase anti-angiogenic factors such as endostatin [20, 24] . It has been proposed that tamoxifen action in breast cancer may be mediated in part by regulation of transforming growth factor beta (TGF-beta) isoforms in tumor tissue; however, the pattern of this regulation are yet not clearly understood. TGF-β1 functions as a tumor promoter by affecting both tumor cell survival and tumor angiogenesis [6, 9] , and an increased expression of TGF-β1 is often seen in tumors of breast cancer patients, which may correlate with poor prognostic outcome [12] . The levels of TGF-β in breast cancer patients treated with tamoxifen have been investigated in several previous studies [29] [30] [31] [32] ; however, most investigations do not provide strong evidence for a generalized Previous studies have shown that a short-term exposure of tamoxifen may induce an increase in TGF-β1 mRNA and activity in MCF-7 cells [35, 36] . In the present study we confirm the results of others by showing an increased protein expression of TGF-β1 after 24 hours of tamoxifen treatment, compared to untreated control cells. However, such short-term treatment poorly represents the clinical treatment with tamoxifen. Our data show that contrary to 24 hours of treatment, long-term treatment (one week in vitro and two weeks in vivo) with tamoxifen generates a decrease in TGF-β1 protein levels, compared to cells not treated with tamoxifen. TGF-β1 may be auto feedback regulated and the elevated 24 hours levels may therefore be involved in a down-regulation the TGF-β1 gene resulting in lowered levels after a period of time. However, after 72 hours of exposure to tamoxifen the levels of TGF-β1 in tamoxifen exposed and control cells were equal. This suggests that, apart from an auto feedback regulation, additional mechanisms may be involved in the regulation of TGF-β1 after long-term treatment with tamoxifen. Here, we show that long-term treatment with tamoxifen may downregulate TGF-β1 via MMP-9 activity.
MMPs have been shown to have multifunctional roles in breast tumor progression.
Instead of merely functioning as key contributors to ECM degradation and thereby promoting tumor cell invasion and angiogenesis, MMPs are now understood to have much broader roles in tumor progression. Recent studies suggest that MMPs may also suppress tumor growth. In this regard we have recently shown that increasing the levels of soluble MMP-9 in human breast cancer in vivo results in increased generation of antiangiogenic fragments, decreased angiogenesis, and decreased tumor growth, and that this may be among the mechanisms that explain the anti-tumorigenic properties of tamoxifen [20, 27] . Here, we show that long-term tamoxifen treatment affects the TGF-β1 protein levels secreted from the breast tumor cells, whereas the intracellular levels of TGF-β1 was unaffected. Interestingly, by inhibiting the extracellular activity of MMP-9, TGF-β1 protein levels were restored. These results suggest a post-translational regulation of TGF-β1 and may point to a novel role for MMPs in the feedback regulation of TGF-β1 activity. Moreover, the down-regulation of TGF-β1 levels may in turn be an additional anti-angiogenic effect of MMP-9 activity.
In summary, we have shown that tamoxifen negatively regulate TGF-β1 protein levels in experimental breast cancer, which in vivo was associated with decreased tumor growth, and decreased angiogenesis. In addition, our in vitro results suggest that the negative regulation of TGF-β1 by tamoxifen is an extracellular event, which, at least in part, involves the activity of MMP-2 and MMP-9.
Our findings provide a novel mechanism by which tamoxifen may exert an antitumorigenic effect in breast cancer, which may be important both for the understanding of sex steroid regulation of breast cancer progression and for future therapeutic strategies against this disease.
